此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Holistic Healing for Knee Osteoarthritis (HEAL-KOA)

2026年8月25日 更新者:Nitesh Manohar Gonnade、All India Institute of Medical Sciences, Jodhpur

Holistic Healing for Knee Osteoarthritis: Comparing Integrated, Standard Medical, and Ayurvedic Care

This study is a single-center, three-arm, open-label randomized controlled trial designed to compare the effectiveness of integrated care, standard medical care, and Ayurvedic care in adults with early knee osteoarthritis (Kellgren-Lawrence grades I-II). Knee osteoarthritis is a leading cause of pain, functional limitation, and reduced quality of life, and current management often provides incomplete symptom relief. Although conventional medical and Ayurvedic interventions are widely used in clinical practice, comparative evidence evaluating these treatment approaches individually and in combination remains limited.

A total of 300 participants aged 30-65 years with primary knee osteoarthritis will be randomly allocated in a 1:1:1 ratio to receive standard medical care, Ayurvedic care, or integrated care. The standard medical care group will receive oral paracetamol, topical diclofenac spray, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy. The Ayurvedic care group will receive Trayodashang Guggulu, Ashwagandha Churna, Janubasti therapy, and topical application of Mahanarayana Taila. The integrated care group will receive Trayodashang Guggulu, Ashwagandha Churna, topical diclofenac spray, and portable transcutaneous electrical nerve stimulation (TENS). Participants will be followed for 24 weeks.

Primary outcome measures include changes in knee pain intensity, knee osteoarthritis symptoms, knee joint surface temperature, and gait kinematic parameters. Secondary outcome measures include changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). The findings of this study are expected to provide evidence regarding the comparative effectiveness of integrated care, standard medical care, and Ayurvedic care in the management of early knee osteoarthritis.

研究概览

详细说明

Knee osteoarthritis (KOA) is one of the most prevalent chronic musculoskeletal disorders and a leading cause of pain, disability, reduced mobility, and impaired quality of life worldwide. Conventional medical management primarily focuses on reducing pain and improving function through pharmacological and non-pharmacological interventions, whereas Ayurvedic management utilizes a holistic approach incorporating herbal medications and external therapeutic procedures. Although both treatment approaches are widely practiced, comparative evidence evaluating conventional medical care, Ayurvedic care, and an integrated treatment approach remains limited. This study aims to compare the effectiveness of these three treatment strategies in individuals with early knee osteoarthritis.

This study is a single-center, three-arm, open-label randomized controlled trial in which 300 participants aged 30-65 years with primary knee osteoarthritis (Kellgren-Lawrence grades I-II) will be randomly allocated in a 1:1:1 ratio to receive standard medical care, Ayurvedic care, or integrated care. Participants will be followed for 24 weeks after randomization. Baseline assessments will include demographic characteristics, clinical examination, radiographic evaluation, and laboratory investigations.

Participants allocated to the Standard Medical Care group will receive oral paracetamol, topical diclofenac spray, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy.

Participants allocated to the Ayurvedic Care group will receive Trayodashang Guggulu, Ashwagandha Churna, Janubasti therapy, and topical application of Mahanarayana Taila.

Participants allocated to the Integrated Care group will receive Trayodashang Guggulu, Ashwagandha Churna, topical diclofenac spray, and portable transcutaneous electrical nerve stimulation (TENS).

The primary objective of the study is to compare the effectiveness of the three treatment approaches in reducing knee pain, improving knee osteoarthritis symptoms, reducing joint inflammation, and improving gait. Primary outcome measures include changes in knee pain intensity assessed using the Visual Analogue Scale (VAS), knee osteoarthritis symptoms assessed using the CRD Pune version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), knee joint surface temperature assessed using infrared thermography, and gait kinematic parameters assessed using three-dimensional gait analysis. Outcome assessments will be performed at baseline and during follow-up according to the study schedule.

Secondary outcome measures include changes in erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) to evaluate systemic inflammation associated with the three treatment approaches.

The findings of this study are expected to provide evidence regarding the comparative effectiveness of integrated care, standard medical care, and Ayurvedic care in improving pain, physical function, joint inflammation, gait, and quality of life among individuals with early knee osteoarthritis. The results may contribute to the development of evidence-based integrative treatment strategies for the management of early knee osteoarthritis.

研究类型

介入性

注册 (估计的)

300

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Rajasthan
      • Jodhpur、Rajasthan、印度、342005
        • All India Institute of Medical Sciences, Jodhpur
        • 接触:
        • 接触:
        • 首席研究员:
          • Nitesh M Gonnade, MBBS, MD(PMR)
        • 副研究员:
          • Meenakshi Sharma, BAMS, MD(Ayurveda)
        • 副研究员:
          • Purvi Purohit, PhD (medical) Biochemistry
        • 副研究员:
          • Kamla K Shukla, Ph.D(Med Biochemistry) Postdoc
        • 副研究员:
          • Om Lata Bhagat, MBBS, MPH, MD (Physiology)
        • 副研究员:
          • Ravi Gaur, MBBS, MD(PMR), DNB(PMR), PGDHM
        • 副研究员:
          • GyanPrakash Sharma, BAMS, MD (Ayurveda)
        • 副研究员:
          • Purnandu Sharma, BAMS, MD (Yoga & Rehab)
        • 副研究员:
          • Sandeep K Yadav, MBBS, MS (Orthopedics)
        • 副研究员:
          • Prem P Sharma, PhD and MSc (Statistics), PSCC
        • 副研究员:
          • Nitesh Gahlot, MS and DNB Ortho, MANMS, FACS
        • 副研究员:
          • Shobhan B Varthya, MBBS, MD(Pharmacology)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age between 30 and 65 years, including males and females both
  • Diagnosis of primary osteoarthritis (OA) affecting at least one knee joint.
  • Kellgren-Lawrence (KL) grading of 1 or 2, indicating mild to moderate OA severity.
  • Baseline Numeric Rating Scale (NRS) score of ≥ 5 out of 10, indicating moderate to severe pain intensity.

Exclusion Criteria:

  • Secondary arthritis due to systemic inflammatory arthritis.
  • History of post-traumatic knee osteoarthritis.
  • Previous total knee replacement (TKR) surgery.
  • Recent corticosteroid use for knee-related conditions.
  • Prior intra-articular viscosupplementation treatment.
  • Allergy to allopathic and Ayurvedic medications used in the study.
  • Concomitant skin disease at the application site of any study intervention.
  • Uncontrolled diabetes mellitus
  • Chronic Renal failure
  • Pregnant and lactating females

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard Medical Care
Participants assigned to this arm will receive standard medical management for knee osteoarthritis for 24 weeks. Treatment includes oral paracetamol, topical diclofenac spray administered as required for pain relief, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy. Participants will be assessed at baseline and followed at 4, 8, 12, 16, 20, and 24 weeks.
Topical diclofenac spray is a non-steroidal anti-inflammatory drug (NSAID) formulation applied locally over the affected knee as required for symptomatic pain relief during the 24-week intervention period.
Portable transcutaneous electrical nerve stimulation (TENS) is a non-invasive electrotherapy device that delivers low-voltage electrical stimulation through surface electrodes placed around the affected knee for pain management during the 24-week intervention period.
Paracetamol is a non-opioid analgesic administered orally for symptomatic pain relief during the 24-week intervention period in the Standard Medical Care group and permitted as rescue (SOS) medication for symptomatic pain relief when clinically required in the Ayurvedic Care and Integrated Care groups.
Superficial heat or cold will be applied locally to the affected knee as a non-pharmacological intervention for symptomatic management of knee osteoarthritis during the 24-week intervention period.
实验性的:Ayurvedic Care
Participants assigned to this arm will receive oral Trayodashang Guggulu (1 g twice daily with lukewarm water), Ashwagandha Churna (3 g twice daily with lukewarm water), Janubasti administered according to the predefined schedule, and topical application of Mahanarayana Taila (10 mL per knee; total 20 mL per application) applied twice daily for 24 weeks. Janubasti will be administered in 21 sessions, with 7 sessions during Weeks 1-2, 7 sessions during Weeks 9-10, and 7 sessions during Weeks 17-18. Participants will undergo scheduled follow-up assessments throughout the study.
Trayodashang Guggulu is an Ayurvedic polyherbal formulation administered orally as tablets at a dose of 1 g twice daily with lukewarm water for 24 weeks for the management of knee osteoarthritis.
Ashwagandha Churna is an Ayurvedic herbal powder derived from the root of Withania somnifera and administered orally at a dose of 3 g twice daily with lukewarm water for 24 weeks.
Janubasti is an Ayurvedic external therapeutic procedure in which warm Mahanarayana Taila is retained over the affected knee within a dough ring for 30-35 minutes. A total of 21 sessions will be administered, with 7 sessions during Weeks 1-2, 7 sessions during Weeks 9-10, and 7 sessions during Weeks 17-18.
Mahanarayana Taila is an Ayurvedic medicated oil applied topically over both knees at a dose of 10 mL per knee (20 mL per application) twice daily for 24 weeks.
实验性的:Integrated Care
Participants assigned to this arm will receive oral Trayodashang Guggulu (1 g twice daily), Ashwagandha Churna (3 g twice daily), topical diclofenac spray as required, and portable transcutaneous electrical nerve stimulation (TENS) for 24 weeks. Participants will undergo scheduled follow-up assessments at Weeks 4, 8, 12, 16, 20, and 24.
Topical diclofenac spray is a non-steroidal anti-inflammatory drug (NSAID) formulation applied locally over the affected knee as required for symptomatic pain relief during the 24-week intervention period.
Portable transcutaneous electrical nerve stimulation (TENS) is a non-invasive electrotherapy device that delivers low-voltage electrical stimulation through surface electrodes placed around the affected knee for pain management during the 24-week intervention period.
Superficial heat or cold will be applied locally to the affected knee as a non-pharmacological intervention for symptomatic management of knee osteoarthritis during the 24-week intervention period.
Trayodashang Guggulu is an Ayurvedic polyherbal formulation administered orally as tablets at a dose of 1 g twice daily with lukewarm water for 24 weeks for the management of knee osteoarthritis.
Ashwagandha Churna is an Ayurvedic herbal powder derived from the root of Withania somnifera and administered orally at a dose of 3 g twice daily with lukewarm water for 24 weeks.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Knee Joint Inflammation Assessed by Infrared Thermography
大体时间:Baseline, Weeks: 4, 8, 12, 16, 20, and 24
Knee joint inflammation will be assessed using infrared thermography by measuring changes in skin surface temperature over the affected knee. The primary outcome measure is the change in thermographic findings from baseline to each scheduled assessment during the 24-week intervention period.
Baseline, Weeks: 4, 8, 12, 16, 20, and 24
Change in Gait Kinematics Assessed Using G-Walk
大体时间:Baseline, Week 12, and Week 24
Gait kinematics will be assessed using the G-Walk system to evaluate changes in gait patterns and mobility. The outcome measure is the change in gait kinematic parameters from baseline to Week 12 and Week 24.
Baseline, Week 12, and Week 24
Change in Knee Pain Intensity Assessed by the Visual Analogue Scale (VAS)
大体时间:Baseline, Weeks: 4, 8, 12, 16, 20 and 24
Knee pain intensity will be assessed using the Visual Analogue Scale, a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity and represent a worse outcome, whereas lower scores indicate less pain intensity and represent a better outcome. The primary outcome measure is the change in Visual Analogue Scale score from baseline to each scheduled assessment during the 24-week intervention period.
Baseline, Weeks: 4, 8, 12, 16, 20 and 24
Change in Physical Function, Pain, and Stiffness Assessed by the CRD Pune Version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
大体时间:Baseline, Weeks: 4, 8, 12, 16, 20, and 24
Physical function, pain and stiffness will be assessed using the validated CRD Pune Version of the Western Ontario and McMaster Universities Osteoarthritis Index. The scale consists of 24 items, each scored from 0 to 4, with a total score ranging from 0 to 96. The Pain domain ranges from 0 to 20, the Stiffness domain from 0 to 8 and the Physical Function domain from 0 to 68. Higher scores indicate greater pain, stiffness and physical functional difficulty and represent a worse outcome, whereas lower scores indicate less pain, stiffness and physical functional difficulty and represent a better outcome. The primary outcome measure is the change in Western Ontario and McMaster Universities Osteoarthritis Index total and domain scores from baseline to each scheduled assessment during the 24-week intervention period.
Baseline, Weeks: 4, 8, 12, 16, 20, and 24

次要结果测量

结果测量
措施说明
大体时间
Change in Erythrocyte Sedimentation Rate (ESR)
大体时间:Baseline and Week 24
Systemic inflammation will be assessed by measuring erythrocyte sedimentation rate (ESR). The outcome measure will be the change in ESR values from baseline.
Baseline and Week 24
Change in Serum C-Reactive Protein (CRP)
大体时间:Baseline and Week 24
Systemic inflammation will be assessed by measuring serum C-reactive protein (CRP). The outcome measure will be the change in CRP concentration from baseline.
Baseline and Week 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nitesh M Gonnade, MBBS, MD(PMR)、All India Institute of Medical Sciences, Jodhpur

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2026年8月12日

首先提交符合 QC 标准的

2026年8月12日

首次发布 (实际的)

2026年8月17日

研究记录更新

最后更新发布 (实际的)

2026年8月27日

上次提交的符合 QC 标准的更新

2026年8月25日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • AIIMS/IEC/2025/5532
  • EMDR/CAR/12/2023-00413 (其他赠款/资助编号:Indian Council of Medical Research (ICMR))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅